par-6 family cell polarity regulator gammaGenealiases: PAR-6G · PAR6gamma
Q-omics provides the consensus-scored PARD6G profile across patient tissues and cancer cell-line models. PARD6G expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PARD6G is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, PARD6G RNA expression shows 19,734 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, THCA, and UVM as cancer lineages where PARD6G shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PARD6G — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PARD6G survival associations across molecular data types. PARD6G RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PARD6G RNA expression–survival associations across cancer types. High PARD6G expression shows unfavorable associations in ACC, LIHC and KICH, but favorable associations in KIRC, HNSC and LAML. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PARD6G RNA expression.
This table summarizes PARD6G tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 2. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for PARD6G. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PARD6G shows lower tumor expression in THCA and KIRP and higher tumor expression in LIHC, LUSC, LUAD and KIRC. The THCA box plot shows higher PARD6G RNA expression in normal versus tumor tissue (log2 FC = −1.352, t-test p < 0.001).
This table shows molecular features associated with PARD6G in patient tissues and cancer cell lines. In patient samples, PARD6G shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PARD6G RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and LARGE_INTESTINE.
